RedHill Biopharma Ltd – (NASDAQ:RDHL) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “RedHill Biopharma focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases, including cancer. RedHill’s proprietary pipeline includes: RHB-105 – a combination therapy for H.pylori infection; RHB-104 – a combination therapy for Crohn’s disease and multiple sclerosis; BEKINDA – a once-daily oral formulation of ondansetron for acute gastroenteritis and IBS-D; RHB-106 – an encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals; YELIVA – an orally-administered first-in-class SK2 selective inhibitor targeting oncology, inflammatory and gastrointestinal indications; MESUPRON – a uPA inhibitor targeting gastrointestinal and other solid tumors; RP101 – currently subject to an option-to-acquire, Hsp27 inhibitor targeting gastrointestinal cancers; RIZAPORT – an oral thin film formulation of rizatriptan for acute migraines. “
Separately, FBR & Co reissued a “buy” rating on shares of RedHill Biopharma Ltd – in a research report on Friday, September 9th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. RedHill Biopharma Ltd – currently has an average rating of “Buy” and an average target price of $26.20.
Shares of RedHill Biopharma Ltd – (NASDAQ:RDHL) opened at 14.10 on Wednesday. The stock’s market capitalization is $179.55 million. RedHill Biopharma Ltd – has a 12-month low of $8.10 and a 12-month high of $16.54. The firm has a 50-day moving average of $14.99 and a 200 day moving average of $12.68.
RedHill Biopharma Ltd – (NASDAQ:RDHL) last issued its quarterly earnings results on Wednesday, July 27th. The company reported ($0.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.52. Equities analysts forecast that RedHill Biopharma Ltd – will post ($2.06) earnings per share for the current fiscal year.
Several large investors have recently added to or reduced their stakes in RDHL. Van ECK Associates Corp raised its stake in shares of RedHill Biopharma Ltd – by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock valued at $105,000 after buying an additional 138 shares in the last quarter. Royal Bank of Canada raised its stake in shares of RedHill Biopharma Ltd – by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock valued at $259,000 after buying an additional 191 shares in the last quarter. Oppenheimer & Co. Inc. bought a new stake in shares of RedHill Biopharma Ltd – during the second quarter valued at approximately $142,000. Finally, Ingalls & Snyder LLC bought a new stake in shares of RedHill Biopharma Ltd – during the second quarter valued at approximately $451,000.
RedHill Biopharma Ltd – Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RedHill Biopharma Ltd - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd - and related companies with MarketBeat.com's FREE daily email newsletter.